Alessandra Bologna
Reggio Nell'emilia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: April 27, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 08, 2026
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.
Journal: Journal of gynecologic oncology
Published: February 05, 2025
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial.
Journal: The International journal of biological markers
Published: November 08, 2024
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 25, 2024
Impact of 2 years of COVID-19 pandemic on ovarian cancer treatment in IRCCS-AUSL of Reggio Emilia.
Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Published: November 11, 2022
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Journal: British journal of cancer
Published: July 29, 2022
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Journal: Gynecologic oncology
Published: July 08, 2022
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Journal: Gynecologic oncology
Published: November 24, 2021
The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
Journal: Diagnostics (Basel, Switzerland)
Published: February 26, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: August 04, 2020
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
Journal: Scientific reports
Published: May 28, 2020
Last Updated: 09/26/2026